1. The Length of Hospital Stay of Patients with Venous Thromboembolism: A Cross-Sectional Study from Jordan.
- Author
-
Amawi, Haneen, Arabyat, Rasha M., Al-Azzam, Sayer, AlZu'bi, Toqa, U'wais, Hamza Tayseer, Hammad, Alaa M., Amawi, Ruba, and Nusair, Mohammad B.
- Subjects
THROMBOEMBOLISM ,LENGTH of stay in hospitals ,VENOUS thrombosis ,ORAL medication ,ELECTRONIC health records - Abstract
Background and Objectives: Venous thromboembolism is one of the leading causes of mortality and disability worldwide. Treatment with anticoagulation therapy is essential and requires a delicate approach to select the most appropriate option to improve patient outcomes, including the length of hospital stay (LOS). The aim of this study was to determine the LOS among patients with acute onset of VTE in several public hospitals in Jordan. Materials and Methods: In this study, we recruited hospitalized patients with a confirmed diagnosis of VTE. We reviewed the electronic medical records and charts of VTE admitted patients in addition to a detailed survey to collect the patients' self-reported data. Hospital LOS was categorized into three levels: 1–3 days, 4–6 days, and ≥7 days. An ordered logistic regression model was used to study the significant predictors of LOS. Results: A total of 317 VTE patients were recruited, with 52.4% of them were male and 35.3% aged between 50 and 69 years. Most patients had a deep vein thrombosis (DVT) diagnosis (84.2%), and most of the VTE cases were admitted for the first-time (64.6%). The majority of the patients were smokers (57.2%), overweight/obese (66.3%), and hypertensive (59%). Most of the VTE patients received Warfarin overlapped with low molecular weight heparins as their treatment regimen (>70%). Almost half of the admitted VTE patients (45%) were hospitalized for at least 7 days. Longer LOS was significantly associated with hypertension. Conclusions: We recommend using therapies that have been proven to reduce hospital LOS, such as non-vitamin K antagonist oral anticoagulants or direct oral anticoagulants, to treat VTE patients in Jordan. Additionally, preventing and controlling comorbidities such as hypertension is essential. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF